STM Journals Peer-reviewed research from Consortium e-Learning Network

International Journal of Cell Biology and Cellular Functions Review Article

Unraveling the Nexus: Parkinson's Disease, Alpha-synuclein, Desulfovibrio, and the Gut Microbiome

  1. Fatima Abdul Azeez Department of biotechnology, Mar Athanasius College, Kothamangalam,

Abstract

Parkinson's disease (PD) is now recognized as a chronic condition which is once considered a highly intricate disorder involving the central, autonomic, and enteric nervous systems. The prevailing perspective attributes the disease by the formation of Lewy bodies, primarily triggered by the misfolding of α-Synuclein, leading to the demise of dopaminergic neurons in the substantia nigra. Constipation, one of the most common non-motor symptoms in PD patients, is believed to be influenced by the composition of gut bacteria. The gastrointestinal tract acts as a significant point of entry through the vagus nerve for potentially harmful microorganisms that can initiate the pathological process of PD. The vagus nerve is proposed to play a role in transmitting signals leading to the over-expression and accumulation of α-Synuclein in the brain. In a study, it was noted that individuals with PD displayed an elevated occurrence of bacteria belonging to the Desulfovibrionaceae family. Desulfovibrio (DSV) are sulfate-reducing bacteria (SRB) that are established as commensal bacteria in the human gastrointestinal tract. Desulfovibrio releases certain metabolites that trigger the aggregation of alpha-synuclein leading to play a role in the pathogenesis of PD. The presence of DSV can lead to a decline in bacterial metabolites, which plays a crucial role in gut health and contributes to the effects observed in individuals with PD. This review consolidates current knowledge on the connection between DSV and PD, emphasizing the role of the gut environment. We address the possibilities that could be considered for reducing the α-Synuclein aggregation in this study by emphasizing Desulfovibrio.

Keywords

References (64)

  1. Nie S, Wang J, Deng Y, Ye Z, Ge Y. Inflammatory microbes and genes as potential biomarkers of Parkinson’s disease. npj Biofilms and Microbiomes. 2022;8(1). doi:10.1038/s41522-022-00367-z
  2. Yamashita KY, Bhoopatiraju S, Silverglate BD, Grossberg GT. Biomarkers in Parkinson’s disease: A state of the art review. Biomarkers in Neuropsychiatry. 2023;9:100074. doi:10.1016/j.bionps.2023.100074
  3. Nakahara K, Nakane S, Ishii K, Ikeda T, Ando Y. Gut microbiota of Parkinson’s disease in an appendectomy cohort: a preliminary study. Scientific Reports. 2023;13(1). doi:10.1038/s41598-023-29219-2
  4. Ryman S, Vakhtin AA, Richardson SP, Lin HC. Microbiome–gut–brain dysfunction in prodromal and symptomatic Lewy body diseases. Journal of Neurology. 2022;270(2):746-758. doi:10.1007/s00415-022-11461-9
  5. Yang X, Qian Y, Xu S, Song Y, Xiao Q. Longitudinal Analysis of Fecal Microbiome and Pathologic Processes in a Rotenone Induced Mice Model of Parkinson’s Disease. Frontiers in Aging Neuroscience. 2018;9. doi:10.3389/fnagi.2017.00441
  6. Ullah H, Arbab S, Tian Y, Liu CQ, Chen Y, Qijie L, et al. The gut microbiota–brain axis in neurological disorder. Frontiers in Neuroscience. 2023;17. doi:10.3389/fnins.2023.1225875
  7. Liu J, Xu F, Nie Z, Shao L. Gut Microbiota Approach—A New Strategy to Treat Parkinson’s Disease. Frontiers in Cellular and Infection Microbiology. 2020;10. doi:10.3389/fcimb.2020.570658
  8. Hey G, Nair N, Klann E, Gurrala A, Safarpour D, Mai V, et al. Therapies for Parkinson’s disease and the gut microbiome: evidence for bidirectional connection. Frontiers in Aging Neuroscience. 2023;15. doi:10.3389/fnagi.2023.1151850
  9. Rajput C, Sarkar A, Sachan N, Rawat N, Singh MP. Is Gut Dysbiosis an Epicenter of Parkinson’s Disease? Neurochemical Research. 2021;46(3):425-438. doi:10.1007/s11064-020-03187-9
  10. Nowak JM, Kopczyński M, Friedman A, Koziorowski D, Figura M. Microbiota Dysbiosis in Parkinson Disease—In Search of a Biomarker. Biomedicines. 2022;10(9):2057. doi:10.3390/biomedicines10092057
  11. Murros KE, Murros K. Hydrogen sulfide produced may induce Parkinson’s disease. Neurosci.
  12. Camerucci E, Stang CD, Hajeb M, Turcano P, Mullan AF, Martin P, et al. Early-onset parkinsonism and early-onset Parkinson’s disease: A population-based study (2010–2015). J Parkinson’s Dis. 2021;11:1197–207. doi:10.3233/JPD-202279.
  13. Sun MF, Shen YQ. Dysbiosis of gut microbiota and microbial metabolites in Parkinson’s Disease. Ageing Research Reviews. 2018;45:53-61. doi:10.1016/j.arr.2018.04.004
  14. Henderson MX, Trojanowski JQ, Lee VMY. α-Synuclein pathology in Parkinson’s disease and related α-synucleinopathies. Neuroscience Letters. 2019;709:134316. doi:10.1016/j.neulet.2019.134316
  15. Srinivasan E, Chandrasekhar G, Chandrasekar P, Anbarasu K, Vickram AS, Karunakaran R, et al. Alpha-Synuclein Aggregation in Parkinson's Disease. Frontiers in Medicine. 2021;8. doi:10.3389/fmed.2021.736978
  16. Perez-Pardo P, Hartog M, Garssen J, Kraneveld AD. Microbes Tickling Your Tummy: the Importance of the Gut-Brain Axis in Parkinson’s Disease. Current Behavioral Neuroscience Reports. 2017;4(4):361-368. doi:10.1007/s40473-017-0129-2
  17. Hirayama M, Nishiwaki H, Hamaguchi T, Ohno K. Gastrointestinal disorders in Parkinson’s disease and other Lewy body diseases. npj Parkinson's Disease. 2023;9(1). doi:10.1038/s41531-023-00511-2
  18. Singh Y, Trautwein C, Romani J, Salker MS, Neckel PH, Fraccaroli I, et al. Overexpression of human alpha-Synuclein leads to dysregulated microbiome/metabolites with ageing in a rat model of Parkinson disease. Molecular Neurodegeneration. 2023;18(1). doi:10.1186/s13024-023-00628-1
  19. Huang Y, Liao J, Liu X, Zhong Y, Cai X, Long L. Review: The Role of Intestinal Dysbiosis in Parkinson’s Disease. Frontiers in Cellular and Infection Microbiology. 2021;11. doi:10.3389/fcimb.2021.615075
  20. Shen T, Yue Y, He T, Huang C, Qu B, Lv W, et al. The Association Between the Gut Microbiota and Parkinson's Disease, a Meta-Analysis. Frontiers in Aging Neuroscience. 2021;13. doi:10.3389/fnagi.2021.636545
  21. Savitt D, Jankovic J. Targeting α-Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics. Drugs. 2019;79(8):797-810. doi:10.1007/s40265-019-01104-1
  22. Fitzgerald E, Murphy S, Martinson HA. Alpha-Synuclein Pathology and the Role of the Microbiota in Parkinson’s Disease. Frontiers in Neuroscience. 2019;13. doi:10.3389/fnins.2019.00369
  23. Chen ZJ, Liang CY, Yang LQ, Ren SM, Xia YM, Cui L, et al. Association of Parkinson’s Disease With Microbes and Microbiological Therapy. Frontiers in Cellular and Infection Microbiology. 2021;11. doi:10.3389/fcimb.2021.619354
  24. Fields CR, Bengoa-Vergniory N, Wade-Martins R. Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease. Frontiers in Molecular Neuroscience. 2019;12. doi:10.3389/fnmol.2019.00299
  25. Munoz-Pinto MF, Empadinhas N, Cardoso SM. The neuromicrobiology of Parkinson’s disease: A unifying theory. Ageing Research Reviews. 2021;70:101396. doi:10.1016/j.arr.2021.101396
  26. Zhu R, Luo Y, Li S, Wang Z. The role of microglial autophagy in Parkinson’s disease. Frontiers in Aging Neuroscience. 2022;14. doi:10.3389/fnagi.2022.1039780
  27. Holmqvist S, Chutna O, Bousset L, Aldrin-Kirk P, Li W, Björklund T, et al. Direct evidence of Parkinson pathology spread from the gastrointestinal tract to the brain in rats. Acta Neuropathologica. 2014;128(6):805-820. doi:10.1007/s00401-014-1343-6
  28. Margolis KG, Cryan JF, Mayer EA. The Microbiota-Gut-Brain Axis: From Motility to Mood. Gastroenterology. 2021;160(5):1486-1501. doi:10.1053/j.gastro.2020.10.066
  29. Calabresi P, Mechelli A, Natale G, Volpicelli-Daley L, Di Lazzaro G, Ghiglieri V. Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death & Disease. 2023;14(3). doi:10.1038/s41419-023-05672-9
  30. Angius F, Mocci I, Ercoli T, Loy F, Fadda L, Palmas MF, et al. Combined measure of salivary alpha-synuclein species as diagnostic biomarker for Parkinson’s disease. Journal of Neurology. 2023;270(11):5613-5621. doi:10.1007/s00415-023-11893-x
  31. Grosso Jasutkar H, Oh SE, Mouradian MM. Therapeutics in the Pipeline Targeting α-Synuclein for Parkinson's Disease. Pharmacological Reviews. 2022;74(1):207-237. doi:10.1124/pharmrev.120.000133
  32. Kalyanaraman B, Cheng G, Hardy M. Gut microbiome, short-chain fatty acids, alpha-synuclein, neuroinflammation, and ROS/RNS: Relevance to Parkinson's disease and therapeutic implications. Redox Biology. 2024;71:103092. doi:10.1016/j.redox.2024.103092
  33. Knorr D, Sinskey AJ. Biotechnology in food production and processing. Science. 1985;229(4719):
  34. 1224-9. doi:10.1126/science.229.4719.1224. PubMed: 17770800.
  35. Ray B, Mahalakshmi AM, Tuladhar S, Bhat A, Srinivasan A, Pellegrino C, et al. “Janus-faced” α-synuclein: Role in Parkinson’s disease. Front Cell Dev Biol. 2021;9:673395. doi:10.3389/fcell.
  36. 2021.673395.
  37. Martin-Gallausiaux C, Marinelli L, Blottière HM, Larraufie P, Lapaque N. SCFA: Mechanisms and functional importance in the gut. Proc Nutr Soc. 2021;37–49.
  38. Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, et al. Gut microbiota: A mechanistic regulator of neurogenesis and therapy in Parkinson’s disease. Neural Regen Res. 2023;18:1684–94. doi:10.4103/1673-5374.358304, PubMed: 37074718.
  39. Baizabal-Carvallo JF, Alonso-Juarez M. The Link between Gut Dysbiosis and Neuroinflammation in Parkinson’s Disease. Neuroscience. 2020;432:160-173. doi:10.1016/j.neuroscience.2020.02.030
  40. Metta V, Leta V, Mrudula KR, Prashanth LK, Goyal V, Borgohain R, et al. Gastrointestinal dysfunction in Parkinson’s disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation. Journal of Neurology. 2021;269(3):1154-1163. doi:10.1007/s00415-021-10567-w
  41. Bi M, Feng L, He J, Liu C, Wang Y, Jiang H, et al. Emerging insights between gut microbiome dysbiosis and Parkinson’s disease: Pathogenic and clinical relevance. Ageing Research Reviews. 2022;82:101759. doi:10.1016/j.arr.2022.101759
  42. Jackson A, Forsyth CB, Shaikh M, Voigt RM, Engen PA, Ramirez V, et al. Diet in Parkinson's Disease: Critical Role for the Microbiome. Frontiers in Neurology. 2019;10. doi:10.3389/fneur.2019.01245
  43. Xie A, Ensink E, Li P, Gordevičius J, Marshall LL, George S, et al. Bacterial Butyrate in Parkinson's Disease Is Linked to Epigenetic Changes and Depressive Symptoms. Movement Disorders. 2022;37(8):1644-1653. doi:10.1002/mds.29128
  44. Cirstea MS, Yu AC, Golz E, Sundvick K, Kliger D, Radisavljevic N, Foulger LH, Mackenzie M, Huan T, Finlay BB, Appel-Cresswell S. Microbiota composition and metabolism are associated with gut function in Parkinson’s disease. Mov Disord. 2020;35(7):1208-17. doi:10.1002/mds.
  45. 28052. PubMed: 32357258.
  46. Thangaleela S, Sivamaruthi BS, Kesika P, Bharathi M, Chaiyasut C. Role of the Gut–Brain Axis, Gut Microbial Composition, Diet, and Probiotic Intervention in Parkinson’s Disease. Microorganisms. 2022;10(8):1544. doi:10.3390/microorganisms10081544
  47. Elford JD, Becht N, Garssen J, Kraneveld AD, Perez-Pardo P. Buty and the beast: The complex role of butyrate in Parkinson’s disease. Front Pharmacol. 2024;15:1388401. doi:10.3389/fphar.
  48. 2024.1388401, PubMed: 38694925.
  49. Murros KE, Huynh VA, Takala TM, Saris PEJ. Desulfovibrio Bacteria Are Associated With Parkinson’s Disease. Frontiers in Cellular and Infection Microbiology. 2021;11. doi:10.3389/fcimb.2021.652617
  50. Sittipo P, Choi J, Lee S, Lee YK. The function of gut microbiota in immune-related neurological disorders: a review. Journal of Neuroinflammation. 2022;19(1). doi:10.1186/s12974-022-02510-1
  51. Santos SF, de Oliveira HL, Yamada ES, Neves BC, Pereira A. The Gut and Parkinson's Disease—A Bidirectional Pathway. Frontiers in Neurology. 2019;10. doi:10.3389/fneur.2019.00574
  52. Suganya K, Koo BS. Gut–Brain Axis: Role of Gut Microbiota on Neurological Disorders and How Probiotics/Prebiotics Beneficially Modulate Microbial and Immune Pathways to Improve Brain Functions. International Journal of Molecular Sciences. 2020;21(20):7551. doi:10.3390/ijms21207551
  53. Wang Q, Luo Y, Ray Chaudhuri K, Reynolds R, Tan EK, Pettersson S. The role of gut dysbiosis in Parkinson’s disease: mechanistic insights and therapeutic options. Brain. 2021;144(9):2571-2593. doi:10.1093/brain/awab156
  54. Zhang F, Wang D. Potential of Akkermansia muciniphila and its outer membrane proteins as therapeutic targets for neuropsychological diseases. Frontiers in Microbiology. 2023;14. doi:10.3389/fmicb.2023.1191445
  55. Hirayama M, Ohno K. Parkinson’s Disease and Gut Microbiota. Annals of Nutrition and Metabolism. 2021;77(Suppl.2):28-35. doi:10.1159/000518147
  56. Hashish S, Salama M. The Role of an Altered Gut Microbiome in Parkinson’s Disease: A Narrative Review. Applied Microbiology. 2023;3(2):429-447. doi:10.3390/applmicrobiol3020030
  57. Singh SB, Carroll-Portillo A, Lin HC. Desulfovibrio in the Gut: The Enemy within? Microorganisms. 2023;11(7):1772. doi:10.3390/microorganisms11071772
  58. Muyzer G, Stams AJM. The ecology and biotechnology of sulphate-reducing bacteria. Nature Reviews Microbiology. 2008;6(6):441-454. doi:10.1038/nrmicro1892
  59. Dordević D, Jančíková S, Vítězová M, Kushkevych I. Hydrogen sulfide toxicity in the gut environment: Meta-analysis of sulfate-reducing and lactic acid bacteria in inflammatory processes. Journal of Advanced Research. 2021;27:55-69. doi:10.1016/j.jare.2020.03.003
  60. Huynh VA, Takala TM, Murros KE, Diwedi B, Saris PEJ. Desulfovibrio bacteria enhance alpha-synuclein aggregation in a Caenorhabditis elegans model of Parkinson’s disease. Frontiers in Cellular and Infection Microbiology. 2023;13. doi:10.3389/fcimb.2023.1181315
  61. Bing G, Liu M. Lipopolysaccharide animal models for Parkinson’s disease. Parkinson’s Dis. 2011.
  62. Rose AH. The Microbiological Production of Food and Drink. Scientific American. 1981;245(3):126-138. doi:10.1038/scientificamerican0981-126
  63. Gorecki AM, Preskey L, Bakeberg MC, Kenna JE, Gildenhuys C, MacDougall G, Dunlop SA, Mastaglia FL, Akkari PA, Koengten F, Anderton RS. Altered gut microbiome in Parkinson’s disease and the influence of lipopolysaccharide in a human α-synuclein over-expressing mouse model. Frontiers in neuroscience. 2019 Aug 7;13:839.
  64. Gorecki AM, Preskey L, Bakeberg MC, Kenna JE, Gildenhuys C, MacDougall G, et al. Altered Gut Microbiome in Parkinson’s Disease and the Influence of Lipopolysaccharide in a Human α-Synuclein Over-Expressing Mouse Model. Frontiers in Neuroscience. 2019;13. doi:10.3389/fnins.2019.00839